BioSpace News Archive

Rheos Medicines, today announced new preclinical data supporting MALT1 inhibition as a novel approach for the treatment of chronic Graft-Versus-Host Disease (cGVHD) and the use of differential metabolic pathway analysis to subset patients in this heterogeneous population.

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in the Phase 2b study performed by Biofrontera Bioscience GmbH to evaluate the safety and efficacy of Ameluz® in combination with the red-light lamp BF-RhodoLED® for the treatment of moderate-to-severe acne with photodynamic therapy (Ameluz®-PDT).

Kura Oncology, Inc. (Nasdaq: KURA), today announced final results from a Phase 2 study of tipifarnib as a monotherapy in patients with relapsed or refractory T-cell lymphoma, including an overall response rate (ORR) of 56% and a median overall survival of 32.8 months in heavily pretreated patients with angioimmunoblastic T-cell lymphoma (AITL).

The CRISPR technology offers the potential to transform medicine, enabling both the treatment or prevention of many illnesses by deleting or inserting genes in a targeted manner.

First Wave BioPharma, Inc. announced that James Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Shareholders in connection with the Company’s 2021 Annual Meeting of Stockholders, to be held on December 17, 2021 at 9:00 a.m. EST.

Kura Oncology, Inc. announced the presentation of new preclinical data for KO-539, the Company’s oral, potent and selective menin inhibitor, and its potential for synergistic activity in combination with venetoclax, a current standard of care in the treatment of patients with acute myeloid leukemia.

Trevena, Inc. (Nasdaq: TRVN), today announced it is advancing TRV045 into clinical development, following receipt of a notification from the U.S. Food and Drug Administration (FDA) that the study may proceed.

Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc. announced a $1 million grant award from the Maryland Department of Housing and Community Development to further support the redevelopment of the Clene manufacturing facility in Elkton, MD.

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. today announced positive results of an interim analysis of overall survival from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial.

CARsgen Therapeutics Holdings Limited today announces that at the 2021 American Society of Hematology (“ASH”) Annual Meeting, the Company presented two posters with study results for CT053, an autologous CAR T-cell product candidate against B-Cell Maturation Antigen (BCMA).